S&P 500   5,138.36 (+0.02%)
DOW   39,035.45 (-0.13%)
QQQ   445.09 (-0.12%)
AAPL   174.09 (-3.10%)
MSFT   416.02 (+0.13%)
META   503.26 (+0.19%)
GOOGL   132.36 (-3.49%)
AMZN   178.76 (+0.30%)
TSLA   189.19 (-6.64%)
NVDA   853.04 (+3.68%)
NIO   5.37 (-7.09%)
AMD   208.38 (+2.83%)
BABA   71.96 (-3.56%)
T   16.94 (-0.24%)
F   13.00 (+4.42%)
MU   96.73 (+1.66%)
CGC   3.03 (-5.61%)
GE   160.20 (+0.98%)
DIS   112.97 (+0.91%)
AMC   4.35 (-0.23%)
PFE   25.91 (-2.56%)
PYPL   59.42 (-1.85%)
XOM   104.45 (-1.31%)
S&P 500   5,138.36 (+0.02%)
DOW   39,035.45 (-0.13%)
QQQ   445.09 (-0.12%)
AAPL   174.09 (-3.10%)
MSFT   416.02 (+0.13%)
META   503.26 (+0.19%)
GOOGL   132.36 (-3.49%)
AMZN   178.76 (+0.30%)
TSLA   189.19 (-6.64%)
NVDA   853.04 (+3.68%)
NIO   5.37 (-7.09%)
AMD   208.38 (+2.83%)
BABA   71.96 (-3.56%)
T   16.94 (-0.24%)
F   13.00 (+4.42%)
MU   96.73 (+1.66%)
CGC   3.03 (-5.61%)
GE   160.20 (+0.98%)
DIS   112.97 (+0.91%)
AMC   4.35 (-0.23%)
PFE   25.91 (-2.56%)
PYPL   59.42 (-1.85%)
XOM   104.45 (-1.31%)
S&P 500   5,138.36 (+0.02%)
DOW   39,035.45 (-0.13%)
QQQ   445.09 (-0.12%)
AAPL   174.09 (-3.10%)
MSFT   416.02 (+0.13%)
META   503.26 (+0.19%)
GOOGL   132.36 (-3.49%)
AMZN   178.76 (+0.30%)
TSLA   189.19 (-6.64%)
NVDA   853.04 (+3.68%)
NIO   5.37 (-7.09%)
AMD   208.38 (+2.83%)
BABA   71.96 (-3.56%)
T   16.94 (-0.24%)
F   13.00 (+4.42%)
MU   96.73 (+1.66%)
CGC   3.03 (-5.61%)
GE   160.20 (+0.98%)
DIS   112.97 (+0.91%)
AMC   4.35 (-0.23%)
PFE   25.91 (-2.56%)
PYPL   59.42 (-1.85%)
XOM   104.45 (-1.31%)
S&P 500   5,138.36 (+0.02%)
DOW   39,035.45 (-0.13%)
QQQ   445.09 (-0.12%)
AAPL   174.09 (-3.10%)
MSFT   416.02 (+0.13%)
META   503.26 (+0.19%)
GOOGL   132.36 (-3.49%)
AMZN   178.76 (+0.30%)
TSLA   189.19 (-6.64%)
NVDA   853.04 (+3.68%)
NIO   5.37 (-7.09%)
AMD   208.38 (+2.83%)
BABA   71.96 (-3.56%)
T   16.94 (-0.24%)
F   13.00 (+4.42%)
MU   96.73 (+1.66%)
CGC   3.03 (-5.61%)
GE   160.20 (+0.98%)
DIS   112.97 (+0.91%)
AMC   4.35 (-0.23%)
PFE   25.91 (-2.56%)
PYPL   59.42 (-1.85%)
XOM   104.45 (-1.31%)
OTCMKTS:BRTX

BioRestorative Therapies (BRTX) Stock Price, News & Analysis

$1.50
+0.10 (+7.14%)
(As of 03/1/2024 08:51 PM ET)
Today's Range
$1.43
$1.57
50-Day Range
$1.28
$3.45
52-Week Range
$1.20
$7.13
Volume
380,800 shs
Average Volume
680,067 shs
Market Capitalization
$7.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

BioRestorative Therapies MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
900.0% Upside
$15.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.52) to ($2.53) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.73 out of 5 stars


BRTX stock logo

About BioRestorative Therapies Stock (OTCMKTS:BRTX)

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

BRTX Stock Price History

BRTX Stock News Headlines

BioRestorative Therapies Inc (BRTX)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Best Light Therapy Lamps for 2023
See More Headlines
Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:BRTX
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$15.00
High Stock Price Target
$15.00
Low Stock Price Target
$15.00
Potential Upside/Downside
+900.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-18,500,000.00
Net Margins
-13,728.83%
Pretax Margin
-13,728.83%

Debt

Sales & Book Value

Annual Sales
$130,200.00
Book Value
$2.65 per share

Miscellaneous

Free Float
3,660,000
Market Cap
$7.06 million
Optionable
Not Optionable
Beta
62.72
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report














BRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioRestorative Therapies stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BRTX shares.
View BRTX analyst ratings
or view top-rated stocks.

What is BioRestorative Therapies' stock price target for 2024?

1 Wall Street research analysts have issued 1 year target prices for BioRestorative Therapies' shares. Their BRTX share price targets range from $15.00 to $15.00. On average, they predict the company's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 900.0% from the stock's current price.
View analysts price targets for BRTX
or view top-rated stocks among Wall Street analysts.

How have BRTX shares performed in 2024?

BioRestorative Therapies' stock was trading at $1.7399 at the start of the year. Since then, BRTX stock has decreased by 13.8% and is now trading at $1.50.
View the best growth stocks for 2024 here
.

When did BioRestorative Therapies' stock split?

BioRestorative Therapies's stock reverse split before market open on Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX) and OPKO Health (OPK).

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:BRTX) was last updated on 3/4/2024 by MarketBeat.com Staff